Moderna experienced a severe 25 percent market drop on Thursday. The selloff was triggered by the apparent premature publication of Phase 3 clinical trial findings for its investigational cancer vaccine, compounded by an earlier downgrade from Citigroup regarding an "unjustifiable" valuation.

By approximately 2 p.m. EDT, Moderna equities tumbled 26 percent to $181.14. Meanwhile, partner firm Merck saw a modest decline of roughly 2 percent.

The downward market pressure materialized after preliminary data regarding the therapeutic cancer immunization surfaced briefly on Oncology Central, a medical news platform, before being swiftly scrubbed from the web.

Although the prematurely revealed findings—officially slated for a Saturday debut—were encouraging, market participants balked at whether the data could support the biotech firm's soaring pre-leak market valuation.

Ultimately, the sudden market correction vaporized nearly $20 billion in total market capitalization for Moderna.

Prior to the Thursday plunge, Moderna had maintained a staggering, albeit precarious, upward trajectory since dropping positive Phase 3 trial data in August. The enterprise reported that its bespoke high-risk melanoma vaccine, designated intismeran, substantially curtailed the probability of cancer recurrence or metastasis to vital organs like the brain, lungs, and liver. Consequently, company shares skyrocketed 290 percent between August 18 and Wednesday. Citigroup analyst Geoff Meacham responded to the surge last month by downgrading the stock from neutral, cautioning that the inflated valuation defied market logic. Citi's economic modeling indicated that justifying the pre-drop share price required roughly $13 billion in annual oncology sales—a figure vastly eclipsing projected commercial outcomes, with the stock trading at nearly seven times realistic cash-flow projections.

WHAT TO KNOW ABOUT THE MODERNA CANCER VACCINE

Designed to be administered following surgical tumor removal, intismeran autogene is a therapeutic vaccine engineered to train patient immune systems to track down and destroy residual micro-tumors beyond the reach of a surgeon's scalpel. Each dose is entirely personalized; Moderna leverages supercomputing analytics to formulate a custom mRNA sequence tailored uniquely to the individual. While the Phase 3 evaluation at the center of the Thursday market selloff appeared promising, granular clinical metrics were originally slated for an official unveiling at a Madrid oncology conference on Saturday.

Prominent billionaire stakeholders absorbed steep contractions in their personal fortunes as equities slid. Chief Executive Officer Stéphane Bancel shed $1.8 billion—roughly 23.5 percent of his net worth—bringing his revised valuation down to $6 billion. Founding investor Timothy Springer dropped $704.8 million, reducing his holdings to $2.6 billion, while co-founder Robert Langer relinquished $696.8 million, marking a 24.6 percent hit to his wealth. Fellow co-founder Noubar Afeyan saw his net worth trimmed by $141.7 million to $2.2 billion, and company president Stephen Hoge sustained a $319.1 million loss, lowering his total net worth to $1.1 billion.